ODI Pharma’s new share issue prior to listing significantly oversubscribed
The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was completed on the 30th of December 2019. The interest was significant, and the Company today announces that the new share issue of a maximum of approximately SEK 25 million was subscribed to approximately 383 percent (incl. pre-subscription commitments), which means that ODI Pharma will receive approximately SEK 25 million before issue costs. The offering that was made available for the public (i.e. not incl. pre-subscription commitments), which represented approximately SEK 7.5 million, was subscribed to 1,039 percent. Through the new share issue, ODI Pharma will receive approximately 1,360 new shareholders.
Derek Simmross, CEO of ODI Pharma, comments
“I want to start by thanking everyone who has shown interest in ODI Pharma by participating in the Company’s new share issue – it is great to see! We are very pleased with the outcome of the capital raise and now look forward to drive the business forward with the help of the raised funds and to help patients in Poland as the first market.”
Subscription and allotment
The new share issue, which amounted to a maximum of approximately SEK 25 million, was subscribed to approximately SEK 95.8 million (incl. pre-subscription commitments of approximately SEK 17.5 million). Allocation of a total of 2,720,000 shares has been decided by the Board of Directors in accordance with the principles set out in the terms in the memorandum. As a result, ODI Pharma will receive SEK 25,024,000 before issue costs of approximately SEK 2.45 million.
Settlement notes are scheduled to be sent out today, the 3rd of January 2020.
Listing on Spotlight Stock Market
The first day of trading in ODI Pharma’s shares on Spotlight Stock Market is expected to be the 23rd of January 2020. The short name for the share will be “ODI” and the ISIN-code is SE0013409760.
Number of shares and share capital
When the recently completed new share issue has been registered at the Swedish Companies Registration Office, ODI Pharma's total number of shares will amount to 15,220,000 and the share capital of the Company will amount to SEK 608,800.00.
Flagging in ODI Pharma
As a result of the new share issue, flagging arises for ODI Pharma's CEO Derek Simmross and Chairman of the Board Volker Wiederrich. Derek Simmross’ and Volker Wiederrich's respective ownership in ODI Pharma before the new share issue amounted to 50 percent each of the shares and capital in the Company. Following the new share issue, Derek Simmross’ and Volker Wiederrich's respective ownership amounts to approximately 42 percent each of the Company's shares and capital.
Financial and legal advisor
Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in the new share issue and the subsequent listing on Spotlight Stock Market.
For more information on ODI Pharma, please contact:
Derek Simmross, CEO, ODI Pharma AB
For more information regarding the new share issue and listing, please contact:
Phone: +46 40 615 14 10
This information is such information that ODI Pharma AB is obliged to disclose in accordance with the EU Market Abuse Regulation. Information was provided, through the above contact person, for publication on the 3rd of January 2020.
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.